I think that was a presentation for the CAR-T licensed to Mustang Bio which targets IL13Ralpha2 , not our CLTX CAR-T. She did another preso on the same treatment earlier in the month if I recall.
This was the earlier CAR-T which showed a complete response in Richard, but has been difficult to replicate consistently across patients since. But the trials are still ongoing.
Our turn will be at the SNO in just over a couple weeks time, and with many more to come as CLTX CAR-T continues to progress through the phase 1 trial.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $9.747M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $15.97K | 4.812M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 68 | 52690500 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 102587679 | 31 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| CHM (ASX) Chart |